Targeting HER2-Driven Disease Beyond the First Line: Antibody-Drug Conjugate Therapy in Gastrointestinal Cancers

Targeting HER2-Driven Disease Beyond the First Line: Antibody-Drug Conjugate Therapy in Gastrointestinal Cancers is organized by Med Learning Group.

Release Date: December 22, 2021
Expiration Date: December 22, 2022

Program Overview:
This enduring activity is a faculty-led didactic and case-based lecture focusing on the management of patients with gastric cancer and colorectal cancer.

Learning Objectives:
Upon completion of the program, attendees should be able to:
• Identify HER2 methods of biomarker testing and apply them to clinical practice in patients with GI malignancies
• Discuss the unique pharmacodynamics of HER2-directed antibody-drug conjugates and their anti-tumor effects in gastrointestinal cancers
• Apply evidence from HER2-targeted, antibody-drug conjugate clinical trials to personalize treatment of patients with advanced GI malignancies beyond the first-line